AAM
CLDX icon

Aberdeen Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Aberdeen Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,516
Closed -$1.2M – 763
2014
Q1 		$1.2M Buy
+4,516
New +$1.73M ﹤0.01% 437

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Aberdeen Asset Management's CLDX Position: Q2 2014 in Review

Aberdeen Asset Management sold out of Celldex Therapeutics (CLDX) in Q2 2014, closing a stake of 4,516 shares — an estimated $1.2M sold.

Aberdeen Asset Management first reported a position in CLDX in Q1 2014 and held it in 1 quarter. The position peaked at $1.2M in Q1 2014. 135 funds tracked by Wall St. Rank hold CLDX as of Q2 2014.

  • Aberdeen Asset Management reported no remaining Celldex Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Aberdeen Asset Management sold 4,516 Celldex Therapeutics shares in Q2 2014, an estimated $1.2M.
  • Aberdeen Asset Management first reported a position in Celldex Therapeutics in Q1 2014 and held it in 1 quarter.
  • Aberdeen Asset Management's Celldex Therapeutics position peaked at $1.2M in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2014.

Based on Aberdeen Asset Management's 13F filing for Q2 2014, filed 24 Jul 2014.